Full coverage for preventive medications after myocardial infarction

Area of Science:

• Cardiology
• Health Economics
• Public Health

Background:

• Medication adherence after myocardial infarction (MI) is often poor.
• Out-of-pocket medication costs may be a significant barrier to adherence.
• Reducing these costs could potentially improve patient outcomes.

Purpose of the Study:

• To evaluate the impact of eliminating prescription drug copayments on medication adherence and clinical outcomes in patients post-myocardial infarction.
• To assess the effect of enhanced prescription coverage on major vascular events and healthcare expenditures.

Main Methods:

• A randomized trial involving insurance-plan sponsors was conducted, assigning them to either full prescription coverage or usual coverage for post-MI medications.
• Patients discharged after MI were enrolled, with outcomes including medication adherence, major vascular events, and health expenditures tracked.
• The primary outcome was defined as the first major vascular event or revascularization.

Main Results:

• Medication adherence rates were significantly higher (4–6 percentage points) in the full-coverage group compared to the usual-coverage group.
• While the primary outcome (first major vascular event or revascularization) did not differ significantly between groups, total major vascular events and the first major vascular event were reduced in the full-coverage group.
• Eliminating copayments did not increase overall health spending and significantly reduced patient out-of-pocket costs for medications and other services.

Conclusions:

• Eliminating copayments for post-MI medications did not significantly affect the primary clinical endpoint.
• Enhanced prescription coverage demonstrably improved medication adherence and reduced specific vascular event rates.
• This approach lowered patient spending on medications without a corresponding increase in total healthcare costs.